| --- | --- | --- | --- | --- | |---------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Cell-Based Therapies | | | | | | | | | | | | A Regenerative Medicine Company | | | | | | September 2022 | | | | | Forward Looking Statements Certain statements in this presentation that are not historical facts are forward-looking statements that reflect management's current expectations, assumptions, and estimates of future performance and economi ...

Longeveron Inc. (NASDAQ:LGVN) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Elsie Yau - Stern Investor Relations Chris Min - Interim Chief Executive Officer & Chief Medical Officer James Clavijo - Chief Financial Officer Joshua Hare - Co-Founder, Chief Science Officer & Chairman Conference Call Participants Michael Okunewitch - Maxim Group Operator Ladies and gentlemen, thank you for standing by. Welcome to the Longeveron 2022 Second Quarter Earnings Call. My name is Irene ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40060 Longeveron Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation) Dela ...

Longeveron Inc. (NASDAQ:LGVN) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Company Participants Elsie Yau - Stern Investor Relations, IR Geoff Green - CEO Chris Min - Chief Medical Officer James Clavijo - CFO Joshua Hare - Chief Science Officer Conference Call Participants Michael Okunewitch - Maxim Group Constantine Davides - EF Hutton Operator Hello everyone and welcome to the Longeveron Inc. 2022 First Quarter Earnings Call. My name is Juan and I will be coordinating your call today. All part ...

Funding and Financials - Longeveron has received over $16.0 million in non-dilutive funding from various organizations, including $11.9 million directly awarded, which is recognized as revenue upon meeting performance obligations[134]. - Revenues for Q1 2022 were approximately $0.4 million, remaining consistent with Q1 2021, while grant revenue decreased by 72% to $0.1 million due to reduced available funds[154]. - Clinical trial revenue from the Bahamas Registry Trial increased by approximately $0.1 million or 88% to $0.3 million in Q1 2022 compared to Q1 2021, attributed to reduced COVID-19 travel restrictions[154]. - General and administrative expenses rose to approximately $2.0 million in Q1 2022, an increase of $0.3 million or 16% from Q1 2021, primarily due to higher compensation and insurance costs[156]. - Net loss for Q1 2022 increased to approximately $3.5 million, a rise of $0.4 million or 13% compared to a net loss of $3.1 million in Q1 2021[161]. - Cash used in operating activities for Q1 2022 was $4.2 million, compared to $3.0 million in Q1 2021, reflecting ongoing operational expenses[164]. - The company anticipates needing additional capital to fund operations, which may come from equity or debt financings, collaborations, or licensing arrangements[167]. - The company has raised approximately $77.2 million in gross proceeds from equity issuance since its formation[168]. - As of March 31, 2022, the company had cash and cash equivalents of $22.1 million and working capital of approximately $29.5 million[168]. - The IPO sold 2,910,000 shares at $10.00 per share, generating gross proceeds of $29.1 million[169]. - The company closed a PIPE offering on December 3, 2021, raising $20.5 million from the sale of 1,169,288 shares at an initial exercise price of $17.50 per share[171]. - The company has been awarded approximately $11.9 million in grants to fund clinical trials and R&D[173]. - The company believes existing cash will fund operations through the first half of 2024, but future funding needs may arise sooner[179]. - As of March 31, 2022, the company has $3.0 million in operating lease obligations and $3.6 million in contract research organization obligations[183]. - The company recognizes grant revenue when related expenses are incurred, with $19,000 recognized from deferred revenue in Q1 2022[190]. Clinical Trials and Product Development - The company is advancing its lead product, Lomecel-B, into later stage clinical trials for multiple indications, including Aging Frailty and Alzheimer's disease[130][134]. - A Phase 2a clinical trial for Lomecel-B in mild Alzheimer's disease has been initiated, enrolling 48 patients across four treatment groups[140]. - The ELPIS II trial for Lomecel-B in infants with Hypoplastic Left Heart Syndrome (HLHS) is ongoing, with all seven planned clinical sites activated for screening and enrollment[140]. - The Phase 1 trial for Lomecel-B in Acute Respiratory Distress Syndrome (ARDS) continues to screen subjects, although enrollment has been slower than expected due to fewer hospitalizations[142]. - The planned Japanese Aging Frailty Phase 2 trial is on track to initiate in the first half of 2022, with top-line results from the Phase 1/2 "HERA" trial expected in the same timeframe[23]. - The company is exploring international expansion, with Japan selected as the first non-U.S. territory for a clinical trial evaluating Lomecel-B for Aging Frailty[134]. Operational and Strategic Focus - Longeveron operates a GMP-compliant manufacturing facility to produce its product candidates, aiming for cost-effective manufacturing to meet future commercial demand[134]. - The company is focused on expanding its intellectual property portfolio to protect its business strategy and enhance the value of its product candidates[134]. - The company aims to leverage collaboration arrangements and out-licensing opportunities to commercialize Lomecel-B and other products domestically and internationally[134]. - Operating costs are expected to increase substantially due to advancements in clinical development and expansion of personnel[178]. Market and Regulatory Status - The company is classified as an "emerging growth company," allowing it to take advantage of reduced reporting requirements under the JOBS Act[199]. - The company will remain an "emerging growth company" until it achieves total annual gross revenues of $1.07 billion or more[200]. - The company will also transition out of this status if it issues more than $1.0 billion in nonconvertible debt within three years[200]. - The company is considered a large accelerated filer if it has a market value exceeding $700 million held by non-affiliates and has been public for at least 12 months[200]. - There were no material changes in the company's exposure to market risk since the last disclosure in the 2021 10-K[203]. Impact of COVID-19 - The impact of the COVID-19 pandemic has been monitored, with minimal disruption to cell production but some challenges in clinical trial follow-ups due to patient reluctance and regional restrictions[135][137].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40060 LONGEVERON INC. (Exact name of registrant as specified in its charter) Delaware 47-2174146 (State or Other Jurisdiction of Inc ...

Longeveron Inc. (NASDAQ:LGVN) Q4 2021 Results Conference Call March 11, 2022 8:30 AM ET Company Participants Brendan Payne - Stern IR Geoff Green - Chief Executive Officer Dr. Joshua Hare - Co-Founder, Chief Science Officer and Chairman James Clavijo - Chief Financial Officer Operator Hello and welcome to Longeveron's call today to discuss the Company's 2021 Fourth Quarter and Year-End Financial Results. All participants are currently in a listen-only mode. Following the formal presentation, we will open th ...

Longeveron Inc. (NASDAQ:LGVN) Q3 2021 Earnings Conference Call November 12, 2021 8:30 AM ET Company Participants Brendan Payne - Stern IR Geoff Green - Chief Executive Officer Joshua Hare - Co-Founder, Chief Science Officer and Chairman James Clavijo - Chief Financial Officer Operator Greetings, and welcome to Longeveron's call today to discuss the results of the company's Third Quarter of 2021 Financial Results. All participants are currently in listen-only mode. Following the formal presentation, we will ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Commission file number: 001-40060 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Longeveron Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-40060 | 47-2174146 | | --- | ...

Financial Data and Key Metrics Changes - Revenues for Q2 2021 were $0.5 million, a decrease of 44% compared to $0.9 million in Q2 2020, primarily due to a reduction in grant revenue [30] - Grant revenue decreased by 68% from $0.9 million in Q2 2020 to $0.3 million in Q2 2021, attributed to the completion of grant-funded clinical trials [30] - Net loss increased to approximately $5 million in Q2 2021 from a net loss of $1.2 million in Q2 2020 [33] - Cash and short-term investments as of June 30, 2021, were $21.4 million, significantly up from $0.8 million as of December 31, 2020, due to the completion of the IPO [33] Business Line Data and Key Metrics Changes - Clinical trial revenue from the Bahamas Registry Trial was $0.2 million in Q2 2021, a 100% increase compared to zero in Q2 2020 [30] - Research and development expenses rose to $2 million in Q2 2021, a 205% increase from $0.7 million in Q2 2020, due to non-reimbursable expenses and increased equity-based compensation [32] - General and administrative expenses increased to $3.2 million in Q2 2021 from $0.6 million in Q2 2020, primarily due to higher compensation and professional expenses [32] Market Data and Key Metrics Changes - The company is actively pursuing multiple clinical trials, including those for Aging Frailty, Alzheimer's disease, and Hypoplastic Left Heart Syndrome, indicating a broad market focus [24][26] - The Phase 2b trial for Lomecel-B showed promising results, with a statistically significant dose-response relationship observed at day 180 [16] Company Strategy and Development Direction - Longeveron aims to advance Lomecel-B as a treatment for Aging Frailty and other chronic diseases, focusing on cell therapies for conditions with no approved treatments [22] - The company is committed to engaging with the FDA and other regulatory bodies to explore clinical and regulatory pathways for future approvals [19] - Plans to initiate a larger Phase 2 study for Alzheimer's disease later this year, indicating a strategic focus on expanding therapeutic applications [25] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the Phase 1 Alzheimer's study results, highlighting the need for further research [25] - The company is well-positioned financially to advance its clinical programs and meet upcoming milestones [35] - Management emphasized the importance of ongoing discussions with regulatory bodies to support the development of Lomecel-B [19] Other Important Information - The Phase 2b trial for Lomecel-B involved 148 subjects and evaluated the safety and efficacy of various doses [9] - The company has received over $15 million in grant funding to support its research initiatives [27] - The upcoming presentation of full trial results at the International Conference of Frailty & Sarcopenia Research is anticipated [19] Q&A Session Summary - The call concluded without any recorded questions or answers, indicating a focus on the presentation of results and updates rather than interactive discussion [36][37]